FILSPARI (sparsentan) – Management of Edema in Patients With IgA Nephropathy in the PROTECT Study
FILSPARI (sparsentan) – Edema and Congestive Heart Failure
FILSPARI (sparsentan) – Drug-Drug Interactions
FILSPARI (sparsentan) – Pharmacokinetic Profile
International Physicians Delphi Survey: Managing Patients With IgA Nephropathy
Sparsentan. Dual Angiotensin II AT1 Receptor Blocker and Endothelin ETA Receptor Antagonist, Treatment of Focal Segmental Glomerulosclerosis, Treatment of IgA Nephropathy
Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)